NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

TB & Outbreaks Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB & Outbreaks Week

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Ebola Hemorrhagic Fever



Research from A.L. Hartman and co-authors yields new data on ebola hemorrhagic fever



August 12th, 2008

"Ebola hemorrhagic fever is a rapidly progressing acute febrile illness characterized by high virus replication, severe immunosuppression, and case fatalities of ca. 80%. Inhibition of phosphorylation of interferon regulatory factor 3 (IRF-3) by the Ebola VP35 protein may block the host innate immune response and play an important role in the severity of disease," researchers in the United States report.

"We used two precisely defined reverse genetics-generated Ebola viruses to investigate global host cell responses resulting from the inhibition of IRF-3 phosphorylation. The two viruses encoded either wild-type (WT) VP35 protein (recEbo-VP35/WT) or VP35 with an arginine...


Source: TB & Outbreaks Week (2008-08-12)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login